News
Generally, fighting cancer is about delivering a relentless attack on the spreading disease, but a new approach explores the ...
On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, ...
The EU-funded project AIDPATH, a collaboration between twelve partners from seven countries, is aiming to increase patient’s access to CAR-T cell therapy, a promising treatment for blood cancers such ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
3d
The Times of Israel on MSNZelig Eshhar, leading cancer researcher and immunologist, dies at 84Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...
From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
4d
News Medical on MSNStudy unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastomaA team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell ...
A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results